利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.026 seconds)

    Novel crystalline form of vegf-r inhibitor
    3.
    发明专利
    Novel crystalline form of vegf-r inhibitor 审中-公开
    VEGF-R抑制剂的新型结晶形式

    公开(公告)号：JP2014193900A

    公开(公告)日：2014-10-09

    申请号：JP2014113765

    申请日：2014-06-02

    Applicant: Pfizer Products Inc ,  ファイザー・プロダクツ・インク

    Inventor： CAMPETA ANTHONY MICHAEL ,  CHEKAL BRIAN PATRICK ,  MCLAUGHLING ROBERT WILLIAM ,  SINGER ROBERT ALAN

    IPC: C07D401/06 ,  A61K31/4439 ,  A61P35/00 ,  A61P43/00

    CPC classification number: C07D401/06

    Abstract: PROBLEM TO BE SOLVED: To provide a novel crystalline polymorphic form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, and to provide methods for preparing the same.SOLUTION: This invention relates to: a crystalline form that has a powder X-ray diffraction pattern comprising a peak at a diffraction angle (2θ) of 6.0±0.1 and further comprising at least one peak at a diffraction angle (2θ) selected from 11.5±0.1, 21.0±0.1 and 26.9±0.1; methods for preparing the same; and pharmaceutical compositions containing at least one polymorphic form.

    Abstract translation: 要解决的问题：提供6- [2-（甲基氨基甲酰基）苯基硫烷基] -3-E- [2-（吡啶-2-基）乙烯基]吲唑的新型结晶多晶型物，并提供其制备方法 本发明涉及：具有粉末X射线衍射图的结晶形式，其衍射角（2θ）为6.0±0.1，并且还包括至少一个衍射角（2θ）处的峰， 选自11.5±0.1,21.0±0.1和26.9±0.1; 制备方法; 和含有至少一种多晶型形式的药物组合物。

    Pyrimidine derivative for treatment of abnormal cell growth
    4.
    发明专利
    Pyrimidine derivative for treatment of abnormal cell growth 审中-公开
    用于治疗异常细胞生长的吡哆醇衍生物

    公开(公告)号：JP2012255038A

    公开(公告)日：2012-12-27

    申请号：JP2012220359

    申请日：2012-10-02

    Applicant: Pfizer Products Inc ,  ファイザー・プロダクツ・インク

    Inventor： KATH JOHN CHARLES ,  LUZZIO MICHAEL JOSEPH ,  LAGRECA SUSAN DEBORAH ,  PATEL NANDINI CHATURBHAI

    IPC: C07D401/14 ,  A61K31/506 ,  A61K45/00 ,  A61P35/00 ,  A61P35/02

    CPC classification number: C07D401/14

    Abstract: PROBLEM TO BE SOLVED: To provide pyrimidine derivatives for the treatment of abnormal cell growth.SOLUTION: The present invention relates to salts, solvates and substoichiometric solvates of N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-N-methylmethanesulfonamide. The invention also provides pharmaceutical compositions comprising such complexes, as well as methods of treating abnormal cell growth by administering the complexes.

    Abstract translation: 待解决的问题：提供用于治疗异常细胞生长的嘧啶衍生物。 解决方案：本发明涉及N- [3 - [[[2 - [（2,3-二氢-2-氧代-1H-吲哚-5-基）氨基] - 吡咯烷酮的盐，溶剂合物和亚化学计量溶剂合物 5-（三氟甲基）-4-嘧啶基]氨基]甲基] -2-吡啶基] -N-甲基甲磺酰胺。 本发明还提供包含这种复合物的药物组合物，以及通过施用复合物治疗异常细胞生长的方法。 版权所有（C）2013，JPO＆INPIT

    Salt form of atorvastatin
    5.
    发明专利
    Salt form of atorvastatin 审中-公开
    ATORVASTATIN的盐形式

    公开(公告)号：JP2012036197A

    公开(公告)日：2012-02-23

    申请号：JP2011201894

    申请日：2011-09-15

    Applicant: Pfizer Products Inc ,  ファイザー・プロダクツ・インク

    Inventor： CAMPETA ANTHONY MICHAEL ,  KRZYZANIAK JOSEPH F ,  LEONARD JASON A

    IPC: C07D207/34 ,  A61K31/40 ,  A61P3/06 ,  A61P15/08 ,  A61P19/10 ,  A61P25/28

    CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

    Abstract: PROBLEM TO BE SOLVED: To provide crystalline forms of atorvastatin sodium and hydrates thereof.SOLUTION: This invention relates to: novel salt forms of [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra; and methods for the preparation and pharmaceutical composition of the same. The salt forms are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

    Abstract translation: 待解决的问题：提供阿托伐他汀钠及其水合物的结晶形式。 解决方案：本发明涉及：[R-（R * ，R * ）的新型盐] 2-（4-氟苯基）-β，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] -1H-吡咯-1-庚酸，其特征在于它们的X射线粉末 衍射图和固体NMR光谱; 及其制备方法和药物组合物。 盐形式可用作治疗高脂血症，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病的药剂。 版权所有（C）2012，JPO＆INPIT

    Hard hydroxypropylmethyl cellulose capsule and manufacturing method
    7.
    发明专利
    Hard hydroxypropylmethyl cellulose capsule and manufacturing method 审中-公开
    硬羟丙基纤维素胶囊和制造方法

    公开(公告)号：JP2013231185A

    公开(公告)日：2013-11-14

    申请号：JP2013123596

    申请日：2013-06-12

    Applicant: Pfizer Products Inc ,  ファイザー・プロダクツ・インク

    Inventor： CADE DOMINIQUE NICOLAS ,  HE XIONGWEI DAVID

    IPC: C08J3/03 ,  A61K9/48 ,  A61K31/167 ,  A61K47/38

    Abstract: PROBLEM TO BE SOLVED: To provide an aqueous composition for manufacturing hard hydroxypropylmethyl cellulose capsule and a manufacturing method.SOLUTION: A hard hydroxypropylmethyl cellulose capsule is manufactured by using a composition comprising a film forming material of hydroxypropylmethyl cellulose including a content of 27.0 to 30.0% (w/w) of methoxy and a content of 4.0 to 7.5% (w/w) of hydroxypropoxy and having a viscosity of 3.5 to 6.0 cPs at 20°C as 2 wt.% solution.

    Abstract translation: 要解决的问题：提供一种制备硬羟丙基甲基纤维素胶囊的水性组合物及其制备方法。解决方案：通过使用包含含量为27.0至30.0％的羟丙基甲基纤维素的成膜材料的组合物制备硬质羟丙基甲基纤维素胶囊， （w / w）甲氧基，含量为4.0〜7.5％（w / w）的羟丙氧基，在20℃下的粘度为3.5〜6.0cPs，为2重量％溶液。

    Anti-ige vaccine
    9.
    发明专利
    Anti-ige vaccine 审中-公开
    抗真菌疫苗

    公开(公告)号：JP2012161322A

    公开(公告)日：2012-08-30

    申请号：JP2012080895

    申请日：2012-03-30

    Applicant: Pfizer Products Inc ,  ファイザー・プロダクツ・インク

    Inventor： MORSEY MOHAMAD A ,  SHEPPARD MICHAEL GEORGE ,  WHEELER DAVID W

    IPC: C12N15/09 ,  A61K39/00 ,  A61K39/39 ,  A61K47/42 ,  A61K48/00 ,  A61P1/00 ,  A61P1/04 ,  A61P11/02 ,  A61P11/06 ,  A61P13/12 ,  A61P27/02 ,  A61P27/14 ,  A61P37/02 ,  A61P37/08 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12P21/02 ,  G01N33/15

    CPC classification number: A61K39/0008 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/00 ,  Y10S424/805 ,  Y10S435/81 ,  Y10S530/868 ,  A61K2300/00

    Abstract: PROBLEM TO BE SOLVED: To provide methods and compositions for treatment of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from CH3 domain or junction of CH3/CH4 domain of an IgE molecule, and to provide methods for the evaluation of IgE-mediated allergies in dogs.SOLUTION: The invention relates to compositions comprising at least one antigenic peptide derived from the CH3 domain or CH3-CH4 domain junction of an IgE molecule coupled to a heterologous carrier protein. The compositions induce anti-IgE antibodies, which bind to soluble IgE in serum and other bodily fluids, but do not cross-link with receptor-bound IgE. The invention relates to methods for administering compositions to animals, preferably mammals and most preferably humans, for the treatment or prevention of IgE-mediated allergic disorders and methods for evaluating vaccines and other therapies for the treating IgE-mediated allergic disorders.

    Abstract translation: 要解决的问题：提供用于治疗IgE介导的过敏性疾病的方法和组合物，其包含免疫原性量的一种或多种衍生自IgE分子的CH3结构域或CH3 / CH4结构域的抗原肽，并提供 用于评估狗中IgE介导的过敏症的方法。 解决方案：本发明涉及包含至少一种衍生自与异源载体蛋白偶联的IgE分子的CH3结构域或CH3-CH4结构域连接的抗原肽的组合物。 组合物诱导抗IgE抗体，其结合血清和其他体液中的可溶性IgE，但不与受体结合的IgE交联。 本发明涉及用于将动物，优选哺乳动物，最优选人类用于治疗或预防IgE介导的过敏性疾病的组合物的方法和用于评估用于治疗IgE介导的过敏性疾病的疫苗和其它疗法的方法。 版权所有（C）2012，JPO＆INPIT

Patent Agency Ranking